The FDA recommends knocking hemodialysis access devices from Class III to Class II devices, making them subject to less-stringent review requirements.
The FDA recommended bumping blood access devices down from Class III to Class II regulatory status, based on mounting evidence that these implanted tubes, catheters and cannulae belong in a lower-risk category.
The federal watchdog agency said there's enough safety and efficacy data to peel off a layer of regulatory oversight. Unlike the highest-risk Class III category, Class II devices are subject special controls, such as labeling rules and performance standards, but are exempt from the FDA's stringent pre-market approval protocol and its attendant clinical trial requirements.
The FDA pulled together draft guidance based on its review of relevant PubMed studies looking at the safety of implanted hemodialysis catheters. The guidance was also based on reports of adverse events and the agency's own pre-market review experience.
Hemodialysis access devices were regulated as Class II until 1983, when the FDA re-categorized them in the highest-risk Class III status. However, based on data gathered since 2009, the agency recommended lowering the risk level a year ago.
The agency said the blood access devices have essentially been regulated as Class II for years. The move would formalize exemption from the rigorous PMA process.
VertiFlex says it won pre-market approval from the FDA for its Superion interspinous spacer.
China is investigating a former top healthcare official on suspicion of bribery.
Medtronic is reportedly looking to grow its presence in China with lower-cost devices, as well as...
Here's a look at some of the top mergers & acquisitions stories for medical device companies this...
A study of replacement heart valves treated with calcification-reducing coatings shows that the...